Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.49 |
| ▸ | DRD3 | P35462 | 6/20 | 0.49 |
| ▸ | DRD4 | P21917 | 4/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | F3 | P13726 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955073 | 0.88 | DRD2 (0.51) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL2948655 | 0.83 | DRD2 (0.71) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL7336826 | 0.82 | DRD2 (0.67) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL8767685 | 0.82 | DRD2 (0.70) | DRD2DRD3DRD4 | |
| SCHEMBL8767680 | 0.82 | DRD2 (0.70) | DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL6844232 | 0.81 | DRD2 (0.65) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| Bromide SCHEMBL7333392 | 0.81 | DRD2 (0.69) | DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL7331896 | 0.81 | DRD2 (0.69) | DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL7331890 | 0.81 | DRD2 (0.69) | DRD2DRD3DRD4 | |
| Bromide SCHEMBL7333395 | 0.81 | DRD2 (0.69) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692096-B1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARM SPA (IT) | 2013-04-03 | — | — | EP | claimed |
| US-7763751-B2 | Hydroxylamine derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-07-27 | — | — | US | claimed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | claimed |
| EP-1541547-A1 | Hydroxylamine derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-15 | — | — | EP | claimed |
| EP-1692096-B1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARM SPA (IT) | 2013-04-03 | — | — | EP | disclosed |
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-05 | — | — | US | disclosed |
| US-7763751-B2 | Hydroxylamine derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-07-27 | — | — | US | disclosed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1541547-A1 | Hydroxylamine derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197799-A1 | HYDROXYLAMINE DERIVATIVES | C9, C1S, HTT | DRD2 392/4885DRD3 245/4885DRD4 167/4885 |
| US-20070049643-A1 | Hydroxylamine derivatives | C9, C1S, HTT | DRD2 332/4885DRD3 161/4885DRD4 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.